CIRCANOL (ergoloid mesylates) by PharmaIN is clinical pharmacology there is no specific evidence which clearly establishes the mechanism by which ergoloid mesylates preparations produce mental effects, nor is there conclusive evidence that the drug particularly affects cerebral arteriosclerosis or cerebrovascular insufficiency. Approved for the treatment of acute, chronic psychosis, regardless of etiology (see ) and 2 more indications. First approved in 1977.
Drug data last refreshed 19h ago
CLINICAL PHARMACOLOGY There is no specific evidence which clearly establishes the mechanism by which ergoloid mesylates preparations produce mental effects, nor is there conclusive evidence that the drug particularly affects cerebral arteriosclerosis or cerebrovascular insufficiency.…
Worked on CIRCANOL at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.